Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure — Hagens Berman Investigating
(NASDAQ:RZLT), SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE) — On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”). The company has billed this drug as […]